These are my preliminary findings and explanations of Trans-D
Tropin.
As you are aware, human growth hormone (hGH) has been shown to have many beneficial
effects such as:
- Decrease in body fat
- Increase in lean muscle mass
- Increase in sexual vigor
- Increase in energy
- Healing of old injuries
- Inhibition of some auto-immune diseases
- Increase in strength
- Improved sleep patterns
- Relief from symptoms of depression
- Increased immune system responses
Normal hGH secretions occur several times during a 24-hour day. During the initial
stages of falling asleep, hGH may increase as much as 200-300%. These normal pulsatile
secretions allow the body to take full advantage of the secreted hGH without causing
dramatic increases of somatostatin, the antagonist of growth hormone.
As the body ages, though still pulsatile in nature, the surges of hGH decline. These
declining levels occur very early in life, after complete height is reached or shortly
thereafter. These secretion levels diminish further with our aging. Other contributing
factors include general physical condition, activity level and diet.
Anti-aging medicine has embraced hGH injections as the Fountain of Youth, however
hGH injections have many drawbacks:
1. HGH is costly, usually between $700 and $1200 per month.
2. HGH injections inhibit the function of our own pituitary gland, as well as that
of the hypothalamus and adrenal gland. No long-term studies have been done to establish
if normal function ever returns.
3. Because of the inhibition of the pituitary gland, other hormone balances are
disrupted. Often cortisone must be used in conjunction with hGH due to the fact
that hGH injections inhibit ACTH secretion.
4. HGH injections increase IGF-1 (Insulin-like growth factor) levels. Increased
IGF-1 levels have been linked to increased rates of growth in both prostate and
breast cancer cells.
Trans-D Tropin is an analogue of Growth Hormone Releasing Hormone (GHRH) that stimulates
the pituitary to produce and release more of our own HGH. In other words, it stimulates
our own body’s production of Human Growth Hormone in a pulsatile manner at every
application time during the day.
This increase in endogenous HGH during the normal 24-hour cycle offers many benefits
over conventional introduction of injected HGH, such as:
- Stimulation of our own pituitary gland, rather than its suppression, should in time
increase its vigor, and preliminary blood work has supported this. This should mean
continuing increases in the overall general health of the endocrine system. Injected
hGH has exactly the opposite effect, by supplying synthetic hGH, the hypothalamus-pituitary-adrenal
axis is effectively inhibited, and no long term studies on adults have been conducted
to discover its long-term effects.
- Much less costly, $175 retail per month, vs. $700-1200 per month for injectable
is a difference, which places this product in the realm of the general public.
- More normal hGH release in a pulsatile manner decreases somatostatin response, therefore
allowing hGH serum levels to remain elevated for 2 hours or more per application.
- Tests have shown consistent decreases in IGF-1 levels using Trans-D Tropin rather
than increases as seen with injectable hGH. This may decrease the likelihood of
increasing cancer growth in some types of cancer.
- Ease of application is greater with topical lotion vs. injection, meaning the applications
may be done at home or on the road at any time.
-
Unlike injectable hGH, there are no allergic reactions to ones own hGH secreted
from ones own pituitary, making this product virtually side effect free.
When evaluating HGH secretagogues, several parameters are measured, which include
HGH, Somatomedin-C (IGF-1), and glucose levels. This is done at the highest normal
dosage level, and is measured against baseline blood levels. This enables us to
measure changes, which occur over a period of time. The following graphs and data
are my findings to date on Trans-D Tropin. I will also discuss my findings and compare
them to similar research I have done with other secretagogues and hGH sprays.
Baseline 30 min. 60 min. 90 min. 53 total tests AVERAGE hGH
VALUES 0.2 0.4 1.8 3.193333 28 test subjects <.5=.2 <.5=.4
This chart shows the rise of serum hGH levels by an average of well over 600% from
baseline. This is an increase of over 3 NG/ML of endogenous hGH. These tests have
been repeated on 28 subjects for over 90 days, and the test results show an average
improvement in pituitary response.
As a comparison, 2,3-butyrolactone (Renewtrient) gave an average HGH increase peak
at 60 minutes at a value of 4.2 NG/ML, but had dropped to an average peak of only
2.38 MG/ML at 60 minutes within 25 days of continued use. 1,4-butanediol (SomatoPro)
gave an average HGH increase peak at 60 minutes at a value of 9.36 NG/ML, but had
dropped to an average peak of only 2.1 MG/ML at 60 minutes within 25 days of continued
use. This demonstrates that consistent use of these secretagogues actually decreases
the pituitary’s response to them, while the hGHRH analogue actually enhances the
pituitary response over time.
Another research finding of 1,4-butanediol and 2,3-butyrolactone is that this major
increase in HGH release was done at the average sleep dose of 25 mg/kg. This may
only be used once daily, at bedtime. For a more normal, pulsatile release of HGH,
Trans-D Tropin is applied three times daily. This much more closely mimics our own
normal biorhythm release of HGH. The cumulative response of an average 3 NG/ML increase
in endogenous HGH, three times daily, far exceeds the once daily initial response
of Renewtrient or SomatoPro. This is true, even in the highest response period of
their use, the first twenty days.
We have also tested a few of the oral HGH sprays which sell from anywhere between
$75.00-$125.00, including Biotropin G TA-5 and HGH Gold oral sprays. None of them
increased serum hGH levels at all. As a matter of fact, none of the oral sprays
changed any of the parameters we were measuring in any consistent manner whatsoever.
With Trans-D Tropin, average glucose levels dropped from 116.574 to 103.5 MG/DL
during the 90-minute test period. This however is a small part of the glucose story.
Glucose levels with Trans-D Tropin seemed to drop for those with high serum glucose
levels.
On the other hand, it tended to rise with those glucose levels
in the mid 70 MG/DL regions.
Though the overall averages for glucose levels tended to drop
from baseline to 90 minutes, I believe it is evident that there tends to be a glucose
modulating effect taking place with Trans-D Tropin.
Frequently IGF-1 levels are used to prove the efficacy of
HGH secretagogues. Recent research findings have shown this to be incorrect. The
use of IGF-1 levels to measure current hGH levels is equally erroneous. As can be
easily seen from the graph, IGF-1 levels have dropped as HGH levels increased.
In the initial research on Trans-D Tropin, overall IGF-1 levels dropped over a 30-day
period, which coincides with the immediate drops during our testing.
Testing showed an average 19.81 NG/ML drop in serum IGF-1
levels within 90 minutes of application during our testing. Baseline IGF-1 levels
have fallen over the 60 days testing as well.
An interesting note is that with 2,3-butyrolactone (Renewtrient)
and 1,4-butanediol (SomatoPro) IGF-1 levels fell as well. Not only do the IGF-1
levels fall as HGH levels rise, but over the long term, they tend to decrease as
well.
This data is important for at least two reasons. The first reason is that IGF-1
has been linked to increasing rates of growth in several types of cancer, including
prostate and breast. The second reason is that many products and medical decisions
are being made concerning HGH secretion and levels using IGF-1 levels.
We have seen in this research that IGF-1 levels do not rise with elevated HGH secretion.
On the other, hand, Inukai T, et al, has found that thyroid hormone modulates insulin-like
growth factor-I(IGF-1) and IGF-binding protein-3, without mediation by growth hormone
in patients with autoimmune thyroid disease.{1} Janssen YJ, et al has found a direct
relationship between serum levels of estradiol and IGF-1 levels, independent of
HGH levels. There is a growing consensus that IGF-1 levels are not a reliable indicator
of HGH levels.{2}
At this time, after over 90 days of testing, I feel that Trans-D Tropin is the safest
and most effective method of raising endogenous hGH levels available.
Current Contraindications for Trans-D Tropin:
- Active cancer of any type
- Pituitary adenoma
- Concurrent use of HGH injections
- Children and Young Adults who have not achieved full height and growth
In order to insure that a pituitary adenoma is not present, it is strongly recommended
that either a Somatomedin-C or Prolactin level be taken through a blood test.
1. Thyroid hormone modulates insulin-like growth factor-1(IGF-1) and IGF-binding
protein3, without mediation by growth hormone, in patients with autoimmune thyroid
disease. Inuki T, Takanashi K, Takebayashi K, Fuiwara Y, Tayama K, Takemura Y Horm
Metab Res 1999 Oct;31 (10):576-9
2. A switch from oral (2 mg/day) to transdermal (50 micro/day) 17beta-estradiol
therapy increases serum insulin-like growth factor-I levels in recombinant human
growth hormone (GH)-substituted women with GH deficiency. Janssen YJ, Helmerhorst
F, Frolich M, Roelfsema F J Clin Endocrinol Metab 2000 Jan;85(1):464-7
SmithKline Beecham Clinical Laboratories did all lab analysis on all samples.
|
|